Last reviewed · How we verify
Synflorix (3-Dose)
Synflorix is a pneumococcal conjugate vaccine that stimulates the body's immune system to produce antibodies against Streptococcus pneumoniae.
Synflorix is a pneumococcal conjugate vaccine that stimulates the body's immune system to produce antibodies against Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease caused by Streptococcus pneumoniae in infants and young children.
At a glance
| Generic name | Synflorix (3-Dose) |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious diseases |
| Phase | Phase 3 |
Mechanism of action
Synflorix works by introducing antigens from various pneumococcal serotypes to the body, which triggers an immune response and the production of antibodies that can recognize and neutralize the bacteria. This immune response helps to protect against invasive pneumococcal disease caused by Streptococcus pneumoniae.
Approved indications
- Prevention of invasive pneumococcal disease caused by Streptococcus pneumoniae in infants and young children
Common side effects
- Pain, redness, swelling, or bruising at the injection site
- Fever
- Vomiting
Key clinical trials
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe (PHASE3)
- Evaluation of PCV Schedules in a Naive Population in Vietnam (PHASE4)
- Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV (PHASE1, PHASE2)
- Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants (PHASE3)
- Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™ (PHASE3)
- Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine (PHASE3)
- Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines (PHASE3)
- Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Synflorix (3-Dose) CI brief — competitive landscape report
- Synflorix (3-Dose) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI